Mycoplasma genitalium in the Far North Queensland backpacker population: An observational study of prevalence and azithromycin resistance

Thomas Trevis; Marianne Gossé; Nicola Santarossa; Sepehr Tabrizi; Darren Russell; William John McBride

doi:10.1371/journal.pone.0202428

Abstract

Background

Mycoplasma genitalium is a sexually transmitted infection (STI), and a common cause of non-gonococcal urethritis (NGU). There is concern regarding the rise in prevalence of M. genitalium and rates of resistance to macrolide antibiotics. International backpackers represent a unique population that may be at an increased risk of STIs. The purpose of this study was to determine the prevalence of M. genitalium and antibiotic resistance in international backpackers.

Methods

First void urine samples were obtained utilising opportunistic sampling from 294 non-treatment-seeking international backpackers at a variety of hostels in Cairns, Queensland Australia. Participants also answered a fixed-answer survey regarding sociodemographic characteristics and sexual risk behaviours. Samples were tested for M. genitalium, Chlamydia trachomatis and Neisseria gonorrhoeae using polymerase chain reaction (PCR). Samples positive for M. genitalium were investigated for macrolide resistance-associated mutations in the 23S rRNA genome at positions A2058G, A2058C, A2058T, A2059G and A2059C (Escherichia coli numbering).

Results

Of the 294 samples, 23 failed the internal control. The prevalence of M. genitalium was 1.8% (5/271, 95% confidence interval [CI] ± 1.58), C. trachomatis was 4.1% (11/271, 95% CI ± 2.36) and N. gonorrhoeae was not detected. Macrolide resistance-associated mutations were identified in 40% (2/5) of M. genitalium-positive samples. M. genitalium infection was associated with reporting symptoms (odds ratio [OR] 14.36, 95% CI 2.17–94.94, p < 0.05).

Conclusions

M. genitalium and C. trachomatis are relatively common amongst non-treatment seeking international backpackers, but may not differ from Australian population prevalence. This article provides evidence to further support the increased utilisation of M. genitalium PCR in the diagnosis of NGU, and for macrolide resistance testing for all identified M. genitalium infections.

Citation: Trevis T, Gossé M, Santarossa N, Tabrizi S, Russell D, McBride WJ (2018) Mycoplasma genitalium in the Far North Queensland backpacker population: An observational study of prevalence and azithromycin resistance. PLoS ONE 13(8): e0202428. https://doi.org/10.1371/journal.pone.0202428

Editor: Chih-Horng Kuo, Academia Sinica, TAIWAN

Received: May 19, 2018; Accepted: August 2, 2018; Published: August 28, 2018

Copyright: © 2018 Trevis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: Data are available from Dryad at https://doi.org/10.5061/dryad.fb45vd1.

Funding: The Cairns Sexual Health Services was a major source of support for this work, providing the necessary funding and equipment required to complete the project. Further funding was sourced through the James Cook University School of Medicine and Dentistry.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Mycoplasma genitalium is a sexually transmitted infection (STI) and an established cause of non-gonococcal urethritis (NGU), being isolated as the most common pathogen in 6–50% of people presenting with NGU [1]. Population prevalence of M. genitalium is estimated in a national Danish study, in a range of 1.1–3.3%; with this same study also suggesting that the prevalence of M. genitalium may be increasing [2]. In Australia, the prevalence of M. genitalium rages from 2.1–13% depending on the population tested [3–6]. The majority of people infected with M. genitalium are likely to be asymptomatic, with 52% asymptomatic in one cohort study [7,8].

Clinical symptoms

Up to 6% of male urogenital complaints may be caused by M. genitalium, which may include: balanoposthitis, urethral discharge and/or dysuria [9–15]. M. genitalium may also be associated with chronic prostatitis and epididymitis [11–16]. In females, M. genitalium is associated with cervicitis, pelvic inflammatory disease, urethritis and infertility [17–19]. M. genitalium has also been associated with preterm birth and spontaneous abortion [19].

Treatment of M. genitalium

In Australia, the mainstay treatment of NGU is single dose 1 gram azithromycin or a 7-day course of doxycycline 100 mg twice daily [20]. One review of recent literature concluded that single-dose azithromycin can induce macrolide resistance and is ineffective if macrolide resistance is present [7]. Although more efficacious than doxycycline (failure rates of up to 83%), azithromycin therapy only resulted in cure of M. genitalium in 40–88% of cases; however, this depended on population resistance levels [7]. Prolonged courses of azithromycin, although slightly more efficacious and less likely to induce macrolide resistance, also remained ineffective if macrolide resistance is already present [7]. In cases of resistance, moxifloxacin 400 mg once daily for 10–14 days remained effective in > 88% of cases, however concerns exist regarding emerging fluoroquinolone resistance in M. genitalium [7].

Macrolide resistance

Resistance to macrolide class antibiotics has become an increasing concern both within recent literature and in clinical practice, with resistance in M. genitalium reported as high as 58.0% in one study investigating attendees at a Canadian sexual health clinic [8]. The first study demonstrating resistance of M. genitalium to macrolide antibiotics, namely azithromycin, was published in 2006 [21]. In 2008, three mutations at the 2058 and 2059 (A2058G, A2059G and A2058C, Escherichia coli numbering) positions in the region V of the 23S rRNA gene were identified to confer clinical macrolide resistance; findings that were consistent with similar research in other Mollicutes [22,23]. Two additional mutations (A2059C and A2058T) were identified using high resolution melt analysis in 2012 [24]. Macrolide resistance-associated mutations have been shown to correlate with microbiological and clinical treatment failure (p = 0.013 and p = 0.024, respectively) [25].

In Australian studies, treatment failure with azithromycin has increased from 16% in a 2005–2007 cohort, to 31% in a 2007–2009 cohort of the same patient population [24,26]. In a recent prospective cohort study, also conducted in Australia, treatment failure with single-dose azithromycin was seen in 39% of participants [27]. Macrolide resistance-associated mutations were detected in 36% of patients, of which 87% failed single-dose azithromycin treatment [27]. These studies suggest that in Australia, resistance-associated mutations in M. genitalium are becoming increasingly prevalent. Alarmingly, a recent study in Greenland detected macrolide resistance-associated mutations in 100% of M. genitalium positive samples [28].

M. genitalium and international travellers

M. genitalium prevalence and antibiotic resistance has not been described in any travelling population. International backpackers are defined as any international traveller staying at least one night in a hostel-style accommodation, and represents an under-studied population in Australia [29]. The prevalence of STI amongst international travellers ranges between 1.6–27.1% for C. trachomatis, 0–36.7% for N. gonorrhoeae, 1.3–24.5% for Treponema pallidum (syphilis), 0.07–1.3% for Trichomonas vaginalis, 1.3–24.5% for herpes simplex virus (HSV), 6.4–9.6% for human papillomavirus (HPV) and 0–4.1% for HIV depending on the study design and specific population sampled [30–39].

Sexually transmissible infections and high-risk sexual behaviour, such as inconsistent condom use and casual sex, alcohol use and engaging in illicit drug use, are reasonably common amongst international travellers in Australia[30–35,40]. During travel, 48–94% of backpackers reported engaging in new sexual partnerships and 41–80% reported inconsistent condom use with new sexual partnerships whilst in Australia [30–34,40]. For this reason, is it believed that backpackers may represent a group at high risk of being infected with M. genitalium.

The aims of this study are to describe the point prevalence of M. genitalium and rates of macrolide resistance-associated mutations within the Far North Queensland backpacker population. Additional primary aims include establishing correlations between M. genitalium positivity and sexual risk behaviour, such as frequency of sexual partners, condom use and travel history.

Methods

Participants

This cross-sectional population-based study was undertaken in Cairns, Queensland Australia between the months of May and June of 2016. During this period, first void urine (FVU) samples and survey data were collected from international backpackers staying in hostel-style accommodation using opportunistic sampling. Permission was sought from the management of these hostels to recruit participants on their premises, provide sexual health information and distribute condoms and water-based lubricants. Hostels in three suburbs of Cairns were contacted, including: sixteen hostels in Cairns City (six agreed to participate) three hostels in Cairns North (all agreed) and one hostel in Parramatta Park (agreed). These hostels were visited in the afternoons and evenings in an attempt to maximise the number of people engaged, as travellers tended to return to hostels from tourist activities in the late afternoon. The research team returned to locations repeatedly, often leaving one or two weeks between visits, until the target sample size was reached. Subjects were only allowed to participate once, however those who requested an additional STI screen were welcome to have one; these additional results did not form part of our dataset. We anticipated a conservative prevalence of 3% in this population, therefore 279 participants would be required to obtain a 95% CI of ± 2%; this figure represents our minimum sample size.

International backpackers aged 18 years or older who have stayed, or are planning to stay, at least 1 night in a backpacker hostel were included in this study. Participants were required to have the capacity to provide informed consent, including sufficient English proficiency to fully understand the consent form. Exclusion criteria prevented the enrolment of those under the age of 18 years and Australian citizens. Participants were approached at random and were provided both written and verbal information about the project. Confectionaries were offered to those who participated, with condoms, personal lubricant, and information about STIs and accessing healthcare in Cairns were freely distributed.

Questionnaire

Written informed consent was obtained from all participants prior to commencing the online survey using the program Google Forms™ (Google Incorporated). Participant provided information included: sociodemographic characteristics, arrival with or without a partner, whether they had stayed at least one night in a backpacker hostel, and their total time thus far in, and total expected stay in, both Australia and Cairns. Included in this survey were a range of questions regarding sexual behaviour, including: the number of sexual partners in the 12 months prior to leaving their country of origin, the number of sexual partners and condom use with these partners whilst in Australia and in Cairns specifically. Travel to a country prior to visiting Australia, the number of sexual partners and condom use in this country were also recorded. Finally, participants provided responses for whether they currently experienced symptoms typical of an STI, whether they had been diagnosed with an STI in the past and whether they had received antibiotic therapy in the last three months S1 File. Participant’s responses were de-identified prior to statistical analysis and re-identified in the event of a positive result. Data were stored in Google Drive™ (Google Incorporated) which requires 2-factor authentication to retrieve.

Specimen collection and analysis

Participants were provided with verbal instruction and asked to supply a FVU sample, all of which were self-collected by participants. Urine specimens were transferred to 1.5 mL micro centrifuge tubes within 3 hours of collection and immediately frozen at –20 degrees Celsius in a freezer with 24-hour temperature monitoring. Following each 4-week period of data collection, samples were sent in a thermal box with a frozen gel pack via overnight courier to The Women’s Hospital in Melbourne, Victoria to undergo molecular testing in two batches. Detection of M. genitalium and macrolide resistance was undertaken simultaneously, utilising the SpeeDx PlexPCR™ M. genitalium ResistancePlus™ assay (SpeeDx Pty. Ltd., Australia) and Roche LightCycler® 480 instruments (Roche Products Pty. Ltd., Australia), following the manufacturer’s instructions for both. This assay determines the presence of M. genitalium by detection of the MgPa gene. This assay simultaneously identifies the presence of 5 mutations at positions A2058G, A2059G, A2058C, A2059C and A2058T (E. coli numbering) in the 23S rRNA genome of M. genitalium associated with resistance to macrolide-based antibiotics. Sensitivity for the detection of M. genitalium using this assay is 99.1% and specificity is 98.5% when compared to reference methods (qPCR targeting the 16S rRNA gene). Sensitivity for detection of macrolide resistance associated mutations is 97.4% and specificity is 100% when compared to reference methods (high resolution melt analysis) [41].

Efficacy of the DNA extraction was assessed and the presence of PCR inhibitors was identified by amplifying a 260bp region of the human beta-globin gene, using methods described in prior literature [42,43]. Detection of C. trachomatis targeting the ompA gene and N. gonorrhoeae targeting the OPA gene was conducted using published in house-assays [44,45]. Samples testing low-positive for the presence of N. gonorrhoeae were confirmed by the detection of the PorA pseudogene using methods previously described [46].

Follow up

Participants with positive test results were contacted with their result and resistance status to best facilitate appropriate care. This was completed by following a semi-scripted ethics-approved re-contact protocol, first by phone (if provided) and then by email.

Data analysis

Specimen data were also entered into Microsoft Excel™ (Microsoft Corporation) and were linked to matched survey data. Data were coded within Excel and analysed by IBM Statistical Package for the Social Sciences version 23™ (International Business Machines Corporation). Proportions with 95% CI were calculated for M. genitalium and C. trachomatis prevalence. Pearson’s chi-squared test for independence (plus Yates’ correction for continuity) and Fisher’s exact test were used to compare categorical variables. Spearman’s ρ correlation coefficient (r) was used to compare continuous variables to dichotomous variables (sex, STI positivity, arrival with sexual partner etc.). Differences between male and female correlation coefficients were performed on all statistically significant correlations, where the critical value of z at p = 0.05 level was ≤ -1.96 or ≥ 1.96, with observed z values (z_obs) outside the critical value of z considered significant.

Ethics

Ethics approval was granted by the James Cook University Human Research Ethics Committee April 26^th 2016. Ethics approval number H6483.

Results

Data were collected from ten locations over twenty-nine separate occasions during the two-month data collection period. Six participants were removed from the dataset due to selecting Australia as their country of origin on the survey. In total, we recruited 157 males (53.0%) and 139 females (47.0%), resulting in a total of 296 completed surveys and 294 FVU samples (two participants were unable to produce urine samples). Of the 294 FVU samples, 23 failed the internal control due to inhibitors in the urine, resulting in 271 valid urine sample results, all with paired survey data.

Participant demographics

The median age of all participants was 23.4 years (interquartile range [IQR] 21.4–26.0). For males, the median age was 23.4 (IQR 21.6–26.2) and for females the median age was 23.1 (IQR 20.9–26.0). Twenty-two-point six percent of all participants were aged 18–20 years, 45.3% were aged 21–24 years and 32.1% were aged ≥ 25 years. The majority of participants originated from European countries (85.5%), with the remainder originating from North America (10.5%), South America (1.4%), Asia (1.4%) and Oceania (0.7%); no participants originated from continental Africa. Of the European counties, 37.8% were from the United Kingdom of Great Britain and Northern Ireland, 18.5% were from Germany, 6.4% were from the Netherlands, 5.7% were from France and 4.4% were from Sweden; 12.9% were from other European countries.

Prevalence of M. genitalium and macrolide resistance

Five samples tested positive for M. genitalium out of the 271 valid urine tests, resulting in a prevalence of 1.8% (5/271, 95% CI ± 1.58). None of these five sample were also positive for C. trachomatis or N. gonorrhoeae. Two people testing positive for M. genitalium reported experiencing symptoms, therefore the asymptomatic prevalence of M. genitalium in this sample was 1.3% (3/240, 95% CI ± 1.43). Independent variables obtained from the survey were explored for associations with M. genitalium positivity, the only statistically significant association identified was reporting symptoms (odds ratio [OR] 14.36, 95% CI 2.17–94.94, relative risk [RR] 12.31, 95% CI 2.25–67.37, p < 0.05). In males, three samples were positive, resulting in a prevalence of 2.2% (3/135, 95% CI ± 2.47). In females, two samples were positive, giving a prevalence of 1.5% (2/136, 95% CI ± 2.04). Of the five positive samples, macrolide resistance-associated mutations were identified in two, demonstrating a 40% rate of resistance in our sample population. The sociodemographic and sexual risk behaviours exhibited by those subjects positive for M. genitalium are outlined in Table 1. Antibiotic use in the past 3 months was reported by 18.9% of participants, with the majority (71.4%) unable to recall what was prescribed.

Download:

Table 1. Sociodemographic and sexual risk behaviour of participants positive for M. genitalium.

https://doi.org/10.1371/journal.pone.0202428.t001

Prevalence of C. trachomatis and N. gonorrhoeae

Eleven samples tested positive for C. trachomatis, resulting in a prevalence of 4.1% (11/271, 95% CI ± 2.36) in our sample population. The number of evaluable asymptomatic subjects was 240, adjusted from 263 for the 23 samples from asymptomatic individuals whose samples exhibited PCR inhibition. Ten participants who tested positive for C. trachomatis denied symptoms and one was uncertain, resulting in an asymptomatic prevalence of 4.2% (10/240, 95% CI ± 2.54). In males, six samples were positive, resulting in a prevalence of 4.4% (6/135, 95% CI ± 3.46). In females, five samples were positive, resulting in a prevalence of 3.7% (5/136, 95% CI ± 3.17). Independent variables obtained from the survey were explored for associations with C. trachomatis positive. Those participants arriving in Australia with a sexual partner were more likely to test positive for C. trachomatis (OR 5.21, 95% CI 1.27–20.34, p < 0.05), however the effect size was small (Cramér’s V [V] = 0.15). There was small but significant correlation between the number of sexual partners engaged with in Cairns and positivity for C. trachomatis (r = .131, p < 0.05), this correlation appeared to be stronger and significant in females (r = .208, p < 0.05 vs r = .038, not significant); however, the correlation coefficient did not differ significantly between groups (z_obs = -1.39). No other statistically significant associations were found between C. trachomatis positivity and surveyed variables, including symptoms. Nine samples were low-positive for N. gonorrhoeae on initial testing, these were shown to be equivocal on confirmation testing of the PorA pseudogene sequence, and therefore considered negative.

Sexual risk behaviour

Table 2 summarises the sexual behaviour of participants, categorised by gender. Twenty-one percent of participants arriving in Australia without a sexual partner engaged in sex with one partner, and 61.0% engaged in sex with 2 or more partners, whilst in Australia. Twenty-point six percent engaged in sex with one sexual partner whilst in Cairns and 24.6% engaged with 2 or more partners in Cairns. Of those engaging in sex with new partners whilst in Australia, 24.5% always used condoms, 38.6% sometimes used condoms, 10.5% used condoms infrequently, and 26.4% never used condoms.

Download:

Table 2. Reported sexual behaviour by gender.

https://doi.org/10.1371/journal.pone.0202428.t002

Discussion

In this cross-sectional population study of 294 non-treatment-seeking international backpackers in Cairns, Queensland Australia, the prevalence of M. genitalium infection was 1.8%, the prevalence of C. trachomatis was 4.1% and the prevalence of N. gonorrhoeae was 0%. Macrolide resistance-associated mutations were identified in 40% of M. genitalium-positive samples. Despite evidence of high risk sexual behaviour, with 61.0% engaging in sexual activity with multiple partners and 75.5% reporting inconsistent or absent condom use, prevalence of M. genitalium was less than that of other Australian population groups, such as 13% in at-risk youth accessing health services, 2.1% in men who have sex with men in men-only saunas and 2.4% in females attending primary healthcare services [6,47,48]. Only one other study has investigated the prevalence of M. genitalium and macrolide resistance in the same geographical area, in a cohort of incarcerated men, where the prevalence was 5.71% and macrolide resistance was 25% [3]. High rates of macrolide resistance have also been reported in other centres within the state of Queensland, with one study reporting macrolide-associated resistance mutations in 63.6% of samples collected from 2011–2017 [49]. The rates of macrolide resistance-associated mutations identified in this study are consistent with that of prior Australian research, and support the notion that resistance is increasing in Australian samples, with 16% identified in a 2005–2007 cohort, 19.5% in a 2007–2008 cohort, 43% in a 2008–2011 cohort, 25% in a 2012–2013 cohort to 40% in our 2016 cohort [3,24,26,50].

Our research supports statements in recent literature calling for increased molecular testing for M. genitalium in primary healthcare environments and recall for test of cure in all patients presenting with M. genitalium-positive NGU [7]. This is becoming increasingly pertinent given the growing body of evidence supporting the long-term and irreversible negative consequences of M. genitalium infection in women. Given the accumulative evidence for the role of M. genitalium in NGU and increasing prevalence of macrolide resistance, our study supports the call to update empirical treatment guidelines for NGU. This is relevant given the overall lack of access to, and utilisation of, M. genitalium PCR testing resulting in a considerable reliance on empirical guidelines in the treatment of NGU. Following the advent of commercially available assays that simultaneously detect M. genitalium and macrolide resistance-associated mutations, increased application of molecular techniques in the diagnosis of NGU and in asymptomatic screening programs have the potential to accurately guide appropriate antibiotic therapy, reduce transmission of resistant strains and prevent long-term consequences of asymptomatic infection [24,41]. In line with recent research, the guidelines for management of PCR-proven M. genitalium infection recommenced by the Australian STI Management Guidelines have changed. Antimicrobial recommendations for M. genitalium infection known or suspected to be susceptible to macrolides includes doxycycline 100 mg twice daily for seven days followed by either azithromycin 1 gram as a single dose or azithromycin 1 gram followed by 500 mg for three days. M. genitalium infection known or suspected to be resistant to macrolides is recommended to be managed with doxycycline 100 mg for seven days followed by moxifloxacin 400 mg for seven days [51]. Despite this further clarity regarding antimicrobial selection for the management of M. genitalium, its routine screening in international backpackers is difficult to support given the low prevalence, uncertainties regarding contact tracing and difficulty with adequate follow up.

The prevalence of C. trachomatis in our study was comparable to a number of other studies in Australia, with one Australian review reporting a mean C. trachomatis prevalence of 4.6% [52]. This was consistent with previous population-level studies of international backpackers in Australia, with 4.3% reported in one recent study and 3.5% in another [30,32]. In two other Australian studies utilising population-level sampling of international backpackers, C. trachomatis rates were higher than reported in this study, at 11.9% in unsupervised screening and 7.7% in sexually active backpackers, both at hostels [31,35]. Higher rates of C. trachomatis infection in international backpackers have been reported, but these studies represented treatment-seeking groups attending sexual health clinics. Our study has been unable to replicate previously-reported associations between age, rates of partner change and inconsistent condom use to C. trachomatis positivity amongst backpackers. This may be a reflection on the small sample size and relatively few positive samples obtained, although our study is not the first to be unable to make any significant association between a variety of sociodemographic factors and sexual behaviours with C. trachomatis positivity in backpackers [32,34]. Inconsistent condom use, reporting 2 or ≥3 sexual partners during travel and reporting a known STI contact were risk factors for C. trachomatis infection in male backpackers in one study, however these may not differ from non-backpacker groups [33].

Prevalence of N. gonorrhoeae in our study was also equivalent to prevalence seen in other population-level studies screening international backpackers, with 0% reported in two studies, and 0.72% in another study of health-seeking backpackers accessing sexual health services; this is likely due to the fact that N. gonorrhoeae is predominately symptomatic and the sample group was mostly asymptomatic [30,31,34].

M. genitalium was associated with reporting STI symptoms, but not in C. trachomatis infection, in our sample. Infection with C. trachomatis was weakly associated with arriving in Australia with a sexual partner. This outcome is likely due to skewed data, as two of the participants testing positive for C. trachomatis were in a long-term monogamous relationship with each other. The number of sexual partners engaged with in Cairns was also associated with C. trachomatis infection, but not the number of sexual partners engaged with in any other location. Engaging in sex with multiple partners whilst in Cairns was reported by 54.5% of those testing positive for C. trachomatis. This may suggest that backpackers actively engage in regular sexual health checks, as rates of partner change are only significantly correlated with C. trachomatis positivity at the most recent travel destination, suggestive of recently obtained infection as opposed to asymptomatic carriage. However regular sexual health seeking behaviour has not been the case in previous reports [30].

Owing to the high frequency of recent antibiotic use, there exists the potential that the prevalence of STIs in this population may be greater than reported. This is especially relevant when considering multiple serovars of C. trachomatis remained susceptible (in varying degrees) to macrolides, tetracyclines, fluoroquinolones and β-lactam antibiotics in a recent in vitro study [53]. Having a past STI diagnosis was reported by 21.6% of participants, consistent with the notion that international travellers report a past diagnosis of STI more often than non-travelling population (15% vs 10%, respectively, p < 0.001), in one Australian study [34].

This study is limited in that the only specimens collected were FVU samples. Evidence suggests that for females, vaginal swab specimens are the most sensitive specimen for the detection of M. genitalium (despite the absence of an established gold standard method for detection of M. genitalium), followed by cervical swabs and then urine samples (κ = .923, κ = .843 and κ = .687 respectively), with another study reporting the sensitivity of 85.7% for vaginal swab samples, 74.3% for endocervical swabs, 61.4% for urine and 24.3% for rectal swabs [54,55]. This may have resulted in an under-representation of M. genitalium-positive females in our study. The overall prevalence of M. genitalium in this population may be higher if other anatomical sites were included. This study is also limited in that a number of other known STIs were not investigated. This was due in part to the financial and logistical constraints of collecting blood samples in a hostel environment and due to a number of other STIs existing beyond the scope of this project. An additional limitation of this study was the number of samples that were unable to be assessed owing to the presence of inhibitors of PCR in the urine. There exists the possibility that subjecting specimens to freeze-thaw cycles may alter the sensitivity of PCR testing. The impact of this limitation could have been decreased with the utilisation of DNA/RNA stabilising agents, allowing samples to be stored at ambient temperature [54]. The sensitivity of the detection of STIs is influenced by the time since last micturition and the participant’s ability to correctly collect a FVU sample, and in females factors such as degree of contamination of urine samples with cervical or vaginal secretions may increase the sensitivity of M. genitalium testing [54]. Further limitations include not assessing additional sexual risk behaviours, such as: alcohol or drug use, time since last STI check, types of sexual activity, or whether participants were utilising the services of sex workers. Participants were also not asked if they were engaging in sex with Australian citizens or other backpackers, which limits this study’s capacity to assess the risk of transmission of STIs and antibiotic resistance from international sources to Australians or vice versa. Another limitation of this study is that there was no formal follow up of STI-positive participants, and therefore we are unable to comment on the relationship between microbiological and clinical macrolide resistance. This study was also limited by the small sample size, and unexpectedly low number of participants testing positive for STIs.

M. genitalium and C. trachomatis were relatively common STIs in our cohort of non-treatment-seeking international backpackers in Cairns, Queensland Australia. International backpackers appear to be a relatively heterogeneous group, and research into this collective may not describe backpackers as a whole. The overall paucity of evidence supporting the categorisation of international backpackers as a high-risk group for STIs and the small volume of evidence suggesting no difference in (and in the case of M. genitalium, reduced) prevalence of STIs when compared to non-travelling groups, makes the justification for outreach sexual health clinics in hostels unfavourable. Concerns regarding the transmission of antibiotic-resistant strains of STIs are supported by a cumulative body of evidence that proposes macrolide resistance-associated mutations are becoming increasingly prevalent in M. genitalium [3,24,26,50]. The unease regarding the spread of antibiotic resistance is heightened when considering the behaviours of sexually active itinerant groups with local populations, and even more so when considering the potential for empirical therapies to induce macrolide resistance in otherwise sensitive M. genitalium strains [7,32,56–58]. Current guidelines regarding the treatment of NGU may be outdated regarding antibiotic resistance patterns, resulting in an environment where selection pressure for the development of resistance is intensified. Despite this evidence, the empirical management of NGU in Australia continues to utilise a 1 gram stat dose of azithromycin, with the intent being to treat chlamydial NGU, which is thought to cause more serious long-term sequelae [59]. However, evidence suggests the potential for significant morbidity associated with M. genitalium, especially in females, and has resulted in appeals within the literature for M. genitalium to be regarded with more significance [7,59,60]. Our research provides continued support for the implementation of now commercially available assays which simultaneously detect M. genitalium and macrolide resistance and regular screening of high risk groups, a risk category international backpackers may inhabit [59]. However, the data does not support a clear public health benefit from hostel-based sexual health outreach services or the regular screening of low to medium risk asymptomatic individuals for M. genitalium.

Supporting information

S1 File. Survey questions.

https://doi.org/10.1371/journal.pone.0202428.s001

(DOCX)

Acknowledgments

Disclaimers. The views expressed in this article are those of the authors’ and do not necessarily reflect the views of James Cook University, James Cook University Human Research Ethics Committee, Cairns Sexual Health Service or Queensland Health.

References

1. Horner P, Blee K, O'Mahony C, Muir P, Evans C, Radcliffe K, et al. 2015 UK National Guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016;27(2):85–96. pmid:26002319
- View Article
- PubMed/NCBI
- Google Scholar
2. Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clinical infectious diseases. 2014;59(1):24–30. pmid:24729494
- View Article
- PubMed/NCBI
- Google Scholar
3. Daley GM, Russell DB, Tabrizi SN, Twin J, McBride WJ. Mycoplasma genitalium and its resistance to azithromycin in incarcerated men from Far North Queensland. Sexual health. 2014;11(6):587–9. pmid:25402451
- View Article
- PubMed/NCBI
- Google Scholar
4. Daley GM, Russell DB, Tabrizi SN, McBride WJ. Mycoplasma genitalium: a review International Journal of STD & AIDS. 2014;25(7):475–87.
- View Article
- Google Scholar
5. Rane VS, Fairley CK, Weerakoon A, Read TH, Fehler G, Chen MY, et al. Characteristics of acute nongonococcal urethritis in men differ by sexual preference. Journal of clinical microbiology. 2014;52(8):2971–6. pmid:24899041
- View Article
- PubMed/NCBI
- Google Scholar
6. Henning D, Eade D, Langstone A, Bean-Hodges A, Marceglia A, Azzopardi P. Asymptomatic Mycoplasma genitalium infection amongst marginalised young people accessing a youth health service in Melbourne. Int J STD AIDS. 2014;25(4):299–302. pmid:24026408
- View Article
- PubMed/NCBI
- Google Scholar
7. Horner P, Blee K, Adams E. Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g! Current opinion in infectious diseases. 2014;27(1):68–74.
- View Article
- Google Scholar
8. Gesink D, Racey S, Seah C, Zittermann S, Mitterni L, Juzkiw J, et al. Mycoplasma genitalium in Toronto, Ont Estimates of prevalence and macrolide resistance. Canadian Family Physician. 2016;62.
- View Article
- Google Scholar
9. van der Veer C, van Rooijen MS, Himschoot M, de Vries HJ, Bruisten SM. Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands. Sexually transmitted infections. 2016;92(1):83–5. pmid:26283740
- View Article
- PubMed/NCBI
- Google Scholar
10. Horner PJ, Taylor-Robinson D. Association of Mycoplasma genitalium with balanoposthitis in men with non-gonococcal urethritis. Sexually transmitted infections. 2011;87(1):38–40. pmid:20852310
- View Article
- PubMed/NCBI
- Google Scholar
11. Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how? Clinical infectious diseases. 2011;53 Suppl 3:S129–42.
- View Article
- Google Scholar
12. Wetmore CMP, Manhart LEP, Lowens MSP, et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis 2011; 38: 180–186. pmid:21285914
- View Article
- PubMed/NCBI
- Google Scholar
13. Sena AC, Lensing S, Rompalo A, et al. Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis 2012; 206: 357–365. pmid:22615318
- View Article
- PubMed/NCBI
- Google Scholar
14. Leung A, Eastick K, Haddon L, et al. Mycoplasma geni- talium is associated with symptomatic urethritis. Int J STD AIDS 2006; 17: 285–288. pmid:16643675
- View Article
- PubMed/NCBI
- Google Scholar
15. Horner PJ, Thomas B, Gilroy CB, et al. Do all men attending departments of genitourinary medicine need to be screened for non-gonococcal urethritis? Int J STD AIDS 2002; 13: 667–673. pmid:12396535
- View Article
- PubMed/NCBI
- Google Scholar
16. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clinical microbiology reviews. 2011;24(3):498–514. pmid:21734246
- View Article
- PubMed/NCBI
- Google Scholar
17. Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis aetiology and case definition: a study in Australian women attending sexually transmitted infection clinics. Sexually transmitted infections. 2016;92(3):175–81. pmid:26586777
- View Article
- PubMed/NCBI
- Google Scholar
18. Ona S, Molina RL, Diouf K. Mycoplasma genitalium: An Overlooked Sexually Transmitted Pathogen in Women? Infectious diseases in obstetrics and gynecology. 2016;2016:4513089. pmid:27212873
- View Article
- PubMed/NCBI
- Google Scholar
19. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015;61(3):418–26.
- View Article
- Google Scholar
20. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2015 Jul.
21. Bradshaw CS, Jensen JS, Tabrizi SN, Read TRH, Garland SM, Hopkins CA, et al. Azithromycin Failure in Mycoplasma genitalium Urethritis. Emerging Infectious Diseases. 2006;12(7):1149–52. pmid:16836839
- View Article
- PubMed/NCBI
- Google Scholar
22. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008;47(12):1546–53.
- View Article
- Google Scholar
23. Vester B, Douthwaite S. Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrobial Agents and Chemotherapy. 2001;45(1):1–12. pmid:11120937
- View Article
- PubMed/NCBI
- Google Scholar
24. Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, et al. Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. PloS one. 2012;7(4):e35593. pmid:22532861
- View Article
- PubMed/NCBI
- Google Scholar
25. Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24(10):822–8. pmid:24052013
- View Article
- PubMed/NCBI
- Google Scholar
26. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium Following Azithromycin Therapy. PloS one. 2008;3(11).
- View Article
- Google Scholar
27. Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clinical infectious diseases. 2015;60(8):1228–36. pmid:25537875
- View Article
- PubMed/NCBI
- Google Scholar
28. Gesink DC, Mulvad G, Montgomery-Andersen R, Poppel U, Montgomery-Andersen S, Binzer A, et al. Mycoplasma genitalium presence, resistance and epidemiology in Greenland. International journal of circumpolar health. 2012;71:1–8.
- View Article
- Google Scholar
29. Tourism Australia, Backpackers uncovered: What do travellers really think of Australia? [Internet]; 2011 [cited June 2016]. Available from: http://www.tourism.australia.com/documents/corporate/Backpackers_uncovered.pdf
30. Fischer JA, Debattista J, Rostami S, Peet AR, Dean JA, Allen KE, et al. Sexual risk taking in a community sample of international backpackers visiting Brisbane, Australia. Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health. 2015;27(2):NP2400–9.
- View Article
- Google Scholar
31. Davies SC, Shepherd B, Wiig R, Kaan I. Unsupervised screening for chlamydia and gonorrhoea in backpacker hostels in Manly, Sydney. Sexual health. 2013;10(2):185–7. pmid:23158843
- View Article
- PubMed/NCBI
- Google Scholar
32. Davies SC, Karagiannis T, Headon V, Wiig R, Duffy J. Prevalence of genital chlamydial infection among a community sample of young international backpackers in Sydney, Australia. International journal of STD & AIDS. 2011;22(3):160–4.
- View Article
- Google Scholar
33. Wand H, Guy R, Donovan B, McNulty A. Population attributable risk for chlamydia infection in a cohort of young international travellers (backpackers) and residents in Australia. BMJ open. 2011;1(1):e000004. pmid:22021720
- View Article
- PubMed/NCBI
- Google Scholar
34. McNulty AM, Egan C, Wand H, Donovan B. The behaviour and sexual health of young international travellers (backpackers) in Australia. Sexually transmitted infections. 2010;86(3):247–50. pmid:20237395
- View Article
- PubMed/NCBI
- Google Scholar
35. Buhrer-Skinner M, Muller R, Menon A, Gordon R. Novel approach to an effective community-based chlamydia screening program within the routine operation of a primary healthcare service. Sexual health. 2009;6:51–6. pmid:19254492
- View Article
- PubMed/NCBI
- Google Scholar
36. Ansart S, Hochedez P, Perez L, Bricaire F, Caumes E. Sexually transmitted diseases diagnosed among travelers returning from the tropics. Journal of travel medicine. 2009;16(2):79–83. pmid:19335805
- View Article
- PubMed/NCBI
- Google Scholar
37. Bavastrelli M, Midulla M, Rossi D, Salzano M, Calzolari E, Midulla C, et al. Sexually Active Adolescents and Young Adults A High-Risk Group for Chlamydia trachomatis Infection. Journal of travel medicine. 1998;5:57–60. pmid:9772318
- View Article
- PubMed/NCBI
- Google Scholar
38. Hawkes S, Hart GJ, Bletsoe E, Shergold C, Johnson AM. Risk behaviour and STD acquisition in genitourinary clinic attenders who have travelled. Genitourin Med. 1995;71:351–4. pmid:8566971
- View Article
- PubMed/NCBI
- Google Scholar
39. Hawkes S, Hart GJ, Johnson AM, Shergold C, Ross E, Herbert KM, et al. Risk behaviour and HIV prevalence in international travellers. AIDS. 1994;8:247–52. pmid:8043230
- View Article
- PubMed/NCBI
- Google Scholar
40. Hughes K, Downing J, Bellis MA, Dillon P, Copeland J. The sexual behaviour of British backpackers in Australia. Sexually transmitted infections. 2009;85(6):477–82. pmid:19826066
- View Article
- PubMed/NCBI
- Google Scholar
41. Tabrizi SN, Tan LY, Walker S, Twin J, Poljak M, Bradshaw CS, et al. Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology. PloS one. 2016;11(6):e0156740. pmid:27271704
- View Article
- PubMed/NCBI
- Google Scholar
42. Resnick R.M., et al., Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst, 1990. 82(18): p. 1477–84. pmid:2167986
- View Article
- PubMed/NCBI
- Google Scholar
43. Cornall A.M., et al., Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer, 2013. 133(9): p. 2253–8. pmid:23616200
- View Article
- PubMed/NCBI
- Google Scholar
44. Stevens M.P., et al., Development and evaluation of an ompA quantitative real-time PCR assay for Chlamydia trachomatis serovar determination. J Clin Microbiol, 2010. 48(6): p. 2060–5. pmid:20392903
- View Article
- PubMed/NCBI
- Google Scholar
45. Tabrizi S.N., et al., Evaluation of opa-based real-time PCR for detection of Neisseria gonorrhoeae. Sex Transm Dis, 2005. 32(3): p. 199–202. pmid:15729160
- View Article
- PubMed/NCBI
- Google Scholar
46. Whiley D.M., et al., A new confirmatory Neisseria gonorrhoeae real-time PCR assay targeting the porA pseudogene. Eur J Clin Microbiol Infect Dis, 2004. 23(9): p. 705–10. pmid:15248092
- View Article
- PubMed/NCBI
- Google Scholar
47. Walker J, Fairley CK, Bradshaw CS, Tabrizi SN, Chen MY, Twin J, et al. 'The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women'. BMC infectious diseases. 2011;11:35. pmid:21284887
- View Article
- PubMed/NCBI
- Google Scholar
48. Bradshaw CS, Fairley CK, Lister NA, Chen SJ, Garland SM, Tabrizi SN. Mycoplasma genitalium in men who have sex with men at male-only saunas. Sexually transmitted infections. 2009;85(6):432–5. pmid:19254902
- View Article
- PubMed/NCBI
- Google Scholar
49. Trembizki E, Buckley C, Bletchly C, Nimmo GR, Whiley DM. High levels of macrolide-resistant Mycoplasma genitalium in Queensland, Australia. Journal of Medical Microbiology. 2017;66:1451–3. pmid:28893363
- View Article
- PubMed/NCBI
- Google Scholar
50. Tagg KA, Jeoffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. Journal of clinical microbiology. 2013;51(7):2245–9. pmid:23658265
- View Article
- PubMed/NCBI
- Google Scholar
51. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. Australian STI Management Guidelines For Use In Primary Care [Internet]; 2018 [cited August 2018]. Available from: http://www.sti.guidelines.org.au/
52. Vajdic CM, Middleton M, Bowden FJ, Fairley CK, Kaldor JM. The prevalence of genital Chlamydia trachomatis in Australia 1997–2004: a systematic review. Sexual health. 2005;2(3):169. pmid:16335545
- View Article
- PubMed/NCBI
- Google Scholar
53. Zheng H, Xue Y, Bai S, Qin X, Lu P, Yang B. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure. Sex Transm Dis. 2015;42(3):115–9. pmid:25668641
- View Article
- PubMed/NCBI
- Google Scholar
54. Wroblewski JK, Manhart LE, Dickey KA, Hudspeth MK, Totten PA. Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium. Journal of clinical microbiology. 2006;44(9):3306–12. pmid:16954265
- View Article
- PubMed/NCBI
- Google Scholar
55. Lillis RA, Nsuami MJ, Myers L, Martin DH. Utility of urine, vaginal, cervical, and rectal specimens for detection of Mycoplasma genitalium in women. Journal of clinical microbiology. 2011;49(5):1990–2. pmid:21411587
- View Article
- PubMed/NCBI
- Google Scholar
56. Cabada MM, Echevarria JI, Seas C, Narvarte G, Samalvides F, Freedman DO, et al. Sexual behavior of international travelers visiting Peru. Sexually transmitted diseases. 2002;29(9):510–3. pmid:12218841
- View Article
- PubMed/NCBI
- Google Scholar
57. Cabada MM, Montoya M, Echevarria JI, Verdonck K, Seas C, Gotuzzo E. Sexual Behavior in Travelers Visiting Cuzco. Journal of travel medicine. 2003;10:214–8. pmid:12946299
- View Article
- PubMed/NCBI
- Google Scholar
58. Cabada MM, Mozo K, Pantenburg B, Gotuzzo E. Excessive alcohol consumption increases risk taking behaviour in travellers to Cusco, Peru. Travel medicine and infectious disease. 2011;9(2):75–81. pmid:21420363
- View Article
- PubMed/NCBI
- Google Scholar
59. Couldwell DL, Lewis DA. Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations. Infection and Drug Resistance 2015;8.
- View Article
- Google Scholar
60. Manhart LE. Mycoplasma genitalium: An Emergent Sexually Transmitted Disease? Infect Dis Clin N Am. 2013:27.
- View Article
- Google Scholar

[ref1] 1. Horner P, Blee K, O'Mahony C, Muir P, Evans C, Radcliffe K, et al. 2015 UK National Guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016;27(2):85–96. pmid:26002319
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clinical infectious diseases. 2014;59(1):24–30. pmid:24729494
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Daley GM, Russell DB, Tabrizi SN, Twin J, McBride WJ. Mycoplasma genitalium and its resistance to azithromycin in incarcerated men from Far North Queensland. Sexual health. 2014;11(6):587–9. pmid:25402451
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Daley GM, Russell DB, Tabrizi SN, McBride WJ. Mycoplasma genitalium: a review International Journal of STD & AIDS. 2014;25(7):475–87.
View Article
Google Scholar

[14] View Article

[15] Google Scholar

[ref5] 5. Rane VS, Fairley CK, Weerakoon A, Read TH, Fehler G, Chen MY, et al. Characteristics of acute nongonococcal urethritis in men differ by sexual preference. Journal of clinical microbiology. 2014;52(8):2971–6. pmid:24899041
View Article
PubMed/NCBI
Google Scholar

[17] View Article

[18] PubMed/NCBI

[19] Google Scholar

[ref6] 6. Henning D, Eade D, Langstone A, Bean-Hodges A, Marceglia A, Azzopardi P. Asymptomatic Mycoplasma genitalium infection amongst marginalised young people accessing a youth health service in Melbourne. Int J STD AIDS. 2014;25(4):299–302. pmid:24026408
View Article
PubMed/NCBI
Google Scholar

[21] View Article

[22] PubMed/NCBI

[23] Google Scholar

[ref7] 7. Horner P, Blee K, Adams E. Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g! Current opinion in infectious diseases. 2014;27(1):68–74.
View Article
Google Scholar

[25] View Article

[26] Google Scholar

[ref8] 8. Gesink D, Racey S, Seah C, Zittermann S, Mitterni L, Juzkiw J, et al. Mycoplasma genitalium in Toronto, Ont Estimates of prevalence and macrolide resistance. Canadian Family Physician. 2016;62.
View Article
Google Scholar

[28] View Article

[29] Google Scholar

[ref9] 9. van der Veer C, van Rooijen MS, Himschoot M, de Vries HJ, Bruisten SM. Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands. Sexually transmitted infections. 2016;92(1):83–5. pmid:26283740
View Article
PubMed/NCBI
Google Scholar

[31] View Article

[32] PubMed/NCBI

[33] Google Scholar

[ref10] 10. Horner PJ, Taylor-Robinson D. Association of Mycoplasma genitalium with balanoposthitis in men with non-gonococcal urethritis. Sexually transmitted infections. 2011;87(1):38–40. pmid:20852310
View Article
PubMed/NCBI
Google Scholar

[35] View Article

[36] PubMed/NCBI

[37] Google Scholar

[ref11] 11. Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how? Clinical infectious diseases. 2011;53 Suppl 3:S129–42.
View Article
Google Scholar

[39] View Article

[40] Google Scholar

[ref12] 12. Wetmore CMP, Manhart LEP, Lowens MSP, et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis 2011; 38: 180–186. pmid:21285914
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref13] 13. Sena AC, Lensing S, Rompalo A, et al. Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis 2012; 206: 357–365. pmid:22615318
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref14] 14. Leung A, Eastick K, Haddon L, et al. Mycoplasma geni- talium is associated with symptomatic urethritis. Int J STD AIDS 2006; 17: 285–288. pmid:16643675
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref15] 15. Horner PJ, Thomas B, Gilroy CB, et al. Do all men attending departments of genitourinary medicine need to be screened for non-gonococcal urethritis? Int J STD AIDS 2002; 13: 667–673. pmid:12396535
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref16] 16. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clinical microbiology reviews. 2011;24(3):498–514. pmid:21734246
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref17] 17. Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis aetiology and case definition: a study in Australian women attending sexually transmitted infection clinics. Sexually transmitted infections. 2016;92(3):175–81. pmid:26586777
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref18] 18. Ona S, Molina RL, Diouf K. Mycoplasma genitalium: An Overlooked Sexually Transmitted Pathogen in Women? Infectious diseases in obstetrics and gynecology. 2016;2016:4513089. pmid:27212873
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref19] 19. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015;61(3):418–26.
View Article
Google Scholar

[70] View Article

[71] Google Scholar

[ref20] 20. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2015 Jul.

[ref21] 21. Bradshaw CS, Jensen JS, Tabrizi SN, Read TRH, Garland SM, Hopkins CA, et al. Azithromycin Failure in Mycoplasma genitalium Urethritis. Emerging Infectious Diseases. 2006;12(7):1149–52. pmid:16836839
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref22] 22. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008;47(12):1546–53.
View Article
Google Scholar

[78] View Article

[79] Google Scholar

[ref23] 23. Vester B, Douthwaite S. Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrobial Agents and Chemotherapy. 2001;45(1):1–12. pmid:11120937
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref24] 24. Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, et al. Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. PloS one. 2012;7(4):e35593. pmid:22532861
View Article
PubMed/NCBI
Google Scholar

[85] View Article

[86] PubMed/NCBI

[87] Google Scholar

[ref25] 25. Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24(10):822–8. pmid:24052013
View Article
PubMed/NCBI
Google Scholar

[89] View Article

[90] PubMed/NCBI

[91] Google Scholar

[ref26] 26. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium Following Azithromycin Therapy. PloS one. 2008;3(11).
View Article
Google Scholar

[93] View Article

[94] Google Scholar

[ref27] 27. Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clinical infectious diseases. 2015;60(8):1228–36. pmid:25537875
View Article
PubMed/NCBI
Google Scholar

[96] View Article

[97] PubMed/NCBI

[98] Google Scholar

[ref28] 28. Gesink DC, Mulvad G, Montgomery-Andersen R, Poppel U, Montgomery-Andersen S, Binzer A, et al. Mycoplasma genitalium presence, resistance and epidemiology in Greenland. International journal of circumpolar health. 2012;71:1–8.
View Article
Google Scholar

[100] View Article

[101] Google Scholar

[ref29] 29. Tourism Australia, Backpackers uncovered: What do travellers really think of Australia? [Internet]; 2011 [cited June 2016]. Available from: http://www.tourism.australia.com/documents/corporate/Backpackers_uncovered.pdf

[ref30] 30. Fischer JA, Debattista J, Rostami S, Peet AR, Dean JA, Allen KE, et al. Sexual risk taking in a community sample of international backpackers visiting Brisbane, Australia. Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health. 2015;27(2):NP2400–9.
View Article
Google Scholar

[104] View Article

[105] Google Scholar

[ref31] 31. Davies SC, Shepherd B, Wiig R, Kaan I. Unsupervised screening for chlamydia and gonorrhoea in backpacker hostels in Manly, Sydney. Sexual health. 2013;10(2):185–7. pmid:23158843
View Article
PubMed/NCBI
Google Scholar

[107] View Article

[108] PubMed/NCBI

[109] Google Scholar

[ref32] 32. Davies SC, Karagiannis T, Headon V, Wiig R, Duffy J. Prevalence of genital chlamydial infection among a community sample of young international backpackers in Sydney, Australia. International journal of STD & AIDS. 2011;22(3):160–4.
View Article
Google Scholar

[111] View Article

[112] Google Scholar

[ref33] 33. Wand H, Guy R, Donovan B, McNulty A. Population attributable risk for chlamydia infection in a cohort of young international travellers (backpackers) and residents in Australia. BMJ open. 2011;1(1):e000004. pmid:22021720
View Article
PubMed/NCBI
Google Scholar

[114] View Article

[115] PubMed/NCBI

[116] Google Scholar

[ref34] 34. McNulty AM, Egan C, Wand H, Donovan B. The behaviour and sexual health of young international travellers (backpackers) in Australia. Sexually transmitted infections. 2010;86(3):247–50. pmid:20237395
View Article
PubMed/NCBI
Google Scholar

[118] View Article

[119] PubMed/NCBI

[120] Google Scholar

[ref35] 35. Buhrer-Skinner M, Muller R, Menon A, Gordon R. Novel approach to an effective community-based chlamydia screening program within the routine operation of a primary healthcare service. Sexual health. 2009;6:51–6. pmid:19254492
View Article
PubMed/NCBI
Google Scholar

[122] View Article

[123] PubMed/NCBI

[124] Google Scholar

[ref36] 36. Ansart S, Hochedez P, Perez L, Bricaire F, Caumes E. Sexually transmitted diseases diagnosed among travelers returning from the tropics. Journal of travel medicine. 2009;16(2):79–83. pmid:19335805
View Article
PubMed/NCBI
Google Scholar

[126] View Article

[127] PubMed/NCBI

[128] Google Scholar

[ref37] 37. Bavastrelli M, Midulla M, Rossi D, Salzano M, Calzolari E, Midulla C, et al. Sexually Active Adolescents and Young Adults A High-Risk Group for Chlamydia trachomatis Infection. Journal of travel medicine. 1998;5:57–60. pmid:9772318
View Article
PubMed/NCBI
Google Scholar

[130] View Article

[131] PubMed/NCBI

[132] Google Scholar

[ref38] 38. Hawkes S, Hart GJ, Bletsoe E, Shergold C, Johnson AM. Risk behaviour and STD acquisition in genitourinary clinic attenders who have travelled. Genitourin Med. 1995;71:351–4. pmid:8566971
View Article
PubMed/NCBI
Google Scholar

[134] View Article

[135] PubMed/NCBI

[136] Google Scholar

[ref39] 39. Hawkes S, Hart GJ, Johnson AM, Shergold C, Ross E, Herbert KM, et al. Risk behaviour and HIV prevalence in international travellers. AIDS. 1994;8:247–52. pmid:8043230
View Article
PubMed/NCBI
Google Scholar

[138] View Article

[139] PubMed/NCBI

[140] Google Scholar

[ref40] 40. Hughes K, Downing J, Bellis MA, Dillon P, Copeland J. The sexual behaviour of British backpackers in Australia. Sexually transmitted infections. 2009;85(6):477–82. pmid:19826066
View Article
PubMed/NCBI
Google Scholar

[142] View Article

[143] PubMed/NCBI

[144] Google Scholar

[ref41] 41. Tabrizi SN, Tan LY, Walker S, Twin J, Poljak M, Bradshaw CS, et al. Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology. PloS one. 2016;11(6):e0156740. pmid:27271704
View Article
PubMed/NCBI
Google Scholar

[146] View Article

[147] PubMed/NCBI

[148] Google Scholar

[ref42] 42. Resnick R.M., et al., Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst, 1990. 82(18): p. 1477–84. pmid:2167986
View Article
PubMed/NCBI
Google Scholar

[150] View Article

[151] PubMed/NCBI

[152] Google Scholar

[ref43] 43. Cornall A.M., et al., Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer, 2013. 133(9): p. 2253–8. pmid:23616200
View Article
PubMed/NCBI
Google Scholar

[154] View Article

[155] PubMed/NCBI

[156] Google Scholar

[ref44] 44. Stevens M.P., et al., Development and evaluation of an ompA quantitative real-time PCR assay for Chlamydia trachomatis serovar determination. J Clin Microbiol, 2010. 48(6): p. 2060–5. pmid:20392903
View Article
PubMed/NCBI
Google Scholar

[158] View Article

[159] PubMed/NCBI

[160] Google Scholar

[ref45] 45. Tabrizi S.N., et al., Evaluation of opa-based real-time PCR for detection of Neisseria gonorrhoeae. Sex Transm Dis, 2005. 32(3): p. 199–202. pmid:15729160
View Article
PubMed/NCBI
Google Scholar

[162] View Article

[163] PubMed/NCBI

[164] Google Scholar

[ref46] 46. Whiley D.M., et al., A new confirmatory Neisseria gonorrhoeae real-time PCR assay targeting the porA pseudogene. Eur J Clin Microbiol Infect Dis, 2004. 23(9): p. 705–10. pmid:15248092
View Article
PubMed/NCBI
Google Scholar

[166] View Article

[167] PubMed/NCBI

[168] Google Scholar

[ref47] 47. Walker J, Fairley CK, Bradshaw CS, Tabrizi SN, Chen MY, Twin J, et al. 'The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women'. BMC infectious diseases. 2011;11:35. pmid:21284887
View Article
PubMed/NCBI
Google Scholar

[170] View Article

[171] PubMed/NCBI

[172] Google Scholar

[ref48] 48. Bradshaw CS, Fairley CK, Lister NA, Chen SJ, Garland SM, Tabrizi SN. Mycoplasma genitalium in men who have sex with men at male-only saunas. Sexually transmitted infections. 2009;85(6):432–5. pmid:19254902
View Article
PubMed/NCBI
Google Scholar

[174] View Article

[175] PubMed/NCBI

[176] Google Scholar

[ref49] 49. Trembizki E, Buckley C, Bletchly C, Nimmo GR, Whiley DM. High levels of macrolide-resistant Mycoplasma genitalium in Queensland, Australia. Journal of Medical Microbiology. 2017;66:1451–3. pmid:28893363
View Article
PubMed/NCBI
Google Scholar

[178] View Article

[179] PubMed/NCBI

[180] Google Scholar

[ref50] 50. Tagg KA, Jeoffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. Journal of clinical microbiology. 2013;51(7):2245–9. pmid:23658265
View Article
PubMed/NCBI
Google Scholar

[182] View Article

[183] PubMed/NCBI

[184] Google Scholar

[ref51] 51. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. Australian STI Management Guidelines For Use In Primary Care [Internet]; 2018 [cited August 2018]. Available from: http://www.sti.guidelines.org.au/

[ref52] 52. Vajdic CM, Middleton M, Bowden FJ, Fairley CK, Kaldor JM. The prevalence of genital Chlamydia trachomatis in Australia 1997–2004: a systematic review. Sexual health. 2005;2(3):169. pmid:16335545
View Article
PubMed/NCBI
Google Scholar

[187] View Article

[188] PubMed/NCBI

[189] Google Scholar

[ref53] 53. Zheng H, Xue Y, Bai S, Qin X, Lu P, Yang B. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure. Sex Transm Dis. 2015;42(3):115–9. pmid:25668641
View Article
PubMed/NCBI
Google Scholar

[191] View Article

[192] PubMed/NCBI

[193] Google Scholar

[ref54] 54. Wroblewski JK, Manhart LE, Dickey KA, Hudspeth MK, Totten PA. Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium. Journal of clinical microbiology. 2006;44(9):3306–12. pmid:16954265
View Article
PubMed/NCBI
Google Scholar

[195] View Article

[196] PubMed/NCBI

[197] Google Scholar

[ref55] 55. Lillis RA, Nsuami MJ, Myers L, Martin DH. Utility of urine, vaginal, cervical, and rectal specimens for detection of Mycoplasma genitalium in women. Journal of clinical microbiology. 2011;49(5):1990–2. pmid:21411587
View Article
PubMed/NCBI
Google Scholar

[199] View Article

[200] PubMed/NCBI

[201] Google Scholar

[ref56] 56. Cabada MM, Echevarria JI, Seas C, Narvarte G, Samalvides F, Freedman DO, et al. Sexual behavior of international travelers visiting Peru. Sexually transmitted diseases. 2002;29(9):510–3. pmid:12218841
View Article
PubMed/NCBI
Google Scholar

[203] View Article

[204] PubMed/NCBI

[205] Google Scholar

[ref57] 57. Cabada MM, Montoya M, Echevarria JI, Verdonck K, Seas C, Gotuzzo E. Sexual Behavior in Travelers Visiting Cuzco. Journal of travel medicine. 2003;10:214–8. pmid:12946299
View Article
PubMed/NCBI
Google Scholar

[207] View Article

[208] PubMed/NCBI

[209] Google Scholar

[ref58] 58. Cabada MM, Mozo K, Pantenburg B, Gotuzzo E. Excessive alcohol consumption increases risk taking behaviour in travellers to Cusco, Peru. Travel medicine and infectious disease. 2011;9(2):75–81. pmid:21420363
View Article
PubMed/NCBI
Google Scholar

[211] View Article

[212] PubMed/NCBI

[213] Google Scholar

[ref59] 59. Couldwell DL, Lewis DA. Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations. Infection and Drug Resistance 2015;8.
View Article
Google Scholar

[215] View Article

[216] Google Scholar

[ref60] 60. Manhart LE. Mycoplasma genitalium: An Emergent Sexually Transmitted Disease? Infect Dis Clin N Am. 2013:27.
View Article
Google Scholar

[218] View Article

[219] Google Scholar

Figures

Abstract

Background

Methods

Results

Conclusions

Introduction

Clinical symptoms

Treatment of M. genitalium

Macrolide resistance

M. genitalium and international travellers

Methods

Participants

Questionnaire

Specimen collection and analysis

Follow up

Data analysis

Ethics

Results

Participant demographics

Prevalence of M. genitalium and macrolide resistance

Prevalence of C. trachomatis and N. gonorrhoeae

Sexual risk behaviour

Discussion

Supporting information

S1 File. Survey questions.

Acknowledgments

References